tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Immunome Inc

IMNM
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
18.770USD
+0.070+0.37%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
2.21B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Immunome Inc ์ •๋ณด ํšŒ์‚ฌ

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Immunome Inc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ IMNM
ํšŒ์‚ฌ ์ด๋ฆ„Immunome Inc
์ƒ์žฅ์ผOct 02, 2020
CEOSiegall (Clay B)
์ง์› ์ˆ˜118
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒOct 02
์ฃผ์†Œ18702 N. Creek Parkway
๋„์‹œBOTHELL
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ98011
์ „ํ™”16103213700
์›น์‚ฌ์ดํŠธhttps://immunome.com/
์ข…๋ชฉ ์ฝ”๋“œ IMNM
์ƒ์žฅ์ผOct 02, 2020
CEOSiegall (Clay B)

Immunome Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
238.96K
--
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
101.29K
+46.65%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
81.16K
-13.61%
Dr. Robert (Bob) Lechleider, M.D.
Dr. Robert (Bob) Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
69.81K
+77.36%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
56.25K
-7.11%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
43.41K
--
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
238.96K
--
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
101.29K
+46.65%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
81.16K
-13.61%
Dr. Robert (Bob) Lechleider, M.D.
Dr. Robert (Bob) Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
69.81K
+77.36%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Immunome Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Immunome Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. Clay B. Siegall, Ph.D.

Immunome Inc(IMNM)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Immunome Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 380๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 116.25M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 102.66%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ 15805031.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ